CURRICULUM VITAE / WISSENSCHAFTLICHER WERDEGANG (short CV)

NAME und KONTAKT

NAME Jutta HOREJS-HOECK (auch HOREJS-HÖCK)

ADRESSE Fachbereich Biowissenschaften und Medizinische Biologie
Universität Salzburg, Hellbrunner Str. 34,
A-5020 Salzburg, Austria, Tel: +43-662-8044-5709
Email: jutta.horejs_hoeck@sbg.ac.at
Website: http://www.uni-salzburg.at/horejs-hoeck
http://orcid.org/0000-0002-0984-204X
ResearcherID: E-5010-2011
https://scholar.google.at/citations

NATIONALITÄT: Österreich

FAMILIENSTAND: verheiratet, 2 Kinder (geboren 2003 und 2006)

AKTUELLE POSITION: Assoziierte Professorin am Fachbereich Biowissenschaften und Medizinische Biologie, Universität Salzburg

BIBLIOGRAPHISCHE DATEN

Jahre in der Wissenschaft: 24
Mutterschaftsurlaub: 1. Kind: 01/2003 – 10/2003
Mutterschaftsurlaub: 2. Kind: 06/2006 – 04/2007
Teilzeitposition als Assistenzprofessorin (50%): 2004 – 2010

RELEVANTE POSITIONEN

seit 2022	Council member der CIVIS European University Alliance (Health Hub)
2018-2022	**stellvertretende Sprecherin** des vom FWF geförderten internationalen PhD-Programms: Immunity in Cancer and Allergy (ICA)
seit 2015	**Prodekanin** der Naturwissenschaftlichen Fakultät, Universität Salzburg, Österreich
seit 07/2014	Assoziierte Professorin am Fachbereich Biowissenschaften, Universität Salzburg, Österreich
2010-2014	Assistenzprofessorin (Tenure Track Position) am Fachbereich Biowissenschaften, Universität Salzburg, Österreich

AUSBILDUNG UND AKADEMISCHER WERDEGANG

07/2014	**Venia docendi**/Habilitation für die Fachgebiete Immunologie und Molekularbiologie
2000-2010	Postgraduate Researcher am Novartis Forschungsinstitut, Wien, der Paris-Lodron-Universität, Salzburg, und dem Telethon-Institut für Gentherapie, Mailand, Italien
2006-2007	Mutterschaftsurlaub, 2. Kind (geboren 7/2006)
2002-2003	Mutterschaftsurlaub, 1. Kind (geb. 1/2003)
1999	**Doktorat** mit Auszeichnung: Novartis Forschungsinstitut, Wien, Österreich/ Universität Salzburg.

STIPENDIEN UND AUSZEICHNUNGEN

2015	AAI Careers in Immunology Fellowship Award AAI
2008	Marie Andeßner Mobilitätsförderpreis
2005	Forschungsstipendium, Gastwissenschaftler in der Gruppe von MG Roncarolo,

	Telethon Institute for Gene-Therapy, Mailand, Italien
2004	Förderstipendium des Landes Salzburg
2002	Theodor-Körner-Förderungspreis

Prof. Dr. Jutta Horejs-Hoeck wurde 1969 in Salzburg geboren. Nach der Matura am Musischen Gymnasium Salzburg (1987) schloss sie 1993 ihr Musikstudium (Klavier) am Mozarteum Salzburg ab und absolvierte 1995 zusätzlich das Diplomstudium Biologie an der Paris Lodron Universität Salzburg. Während ihres Doktoratsstudiums forschte sie am Novartis Forschungsinstitut in Wien an neuen therapeutischen Molekülen zur Hemmung von Allergie-vermittelnden IgE-Antikörpern. Nach der Promotion (1999) folgte ein weiterer dreijähriger Forschungsaufenthalt am Novartis Research Institute mit dem Ziel, neue Signalwege zu identifizieren, die mit allergischen Reaktionen in Zusammenhang stehen und daher therapeutisch genutzt werden könnten.

Nach weiteren Forschungsaufenthalten am Fachbereich für Molekulare Biologie der Paris Lodron Universität Salzburg und am renommierten Telethon Institute for Gene-Therapy in Mailand, Italien, habilitierte sich Jutta Horejs-Hoeck 2014 in den Fächern Immunologie und Molekularbiologie an der Paris Lodron Universität Salzburg, wo sie seither als assoziierte Universitätsprofessorin tätig ist. Ihre Forschungsschwerpunkte, die in zahlreichen Publikationen (~60 Zitationen/Publikation) dokumentiert sind, liegen im Bereich der chronischen Entzündung, wo sie sich besonders für Entzündungsprozesse als Risikofaktoren für Krebserkrankungen interessiert.

Jutta Horejs-Hoeck leitet eine forschungsstarke Arbeitsgruppe am Fachbereich für Biowissenschaften und Medizinische Biologie, ist in zahlreichen wissenschaftlichen Organisationen aktiv, Mitglied des Review Panels für den Johann Wilhelm Ritter von Mannagetta-Preis der Österreichischen Akademie der Wissenschaften und Council Member der CIVIS University Alliance. Sie war von 2018 bis 2022 stellvertretende Sprecherin des FWF-geförderten Doktoratskollegs „Immunity in Cancer and Allergy (ICA)“ und ist seit 2015 als Vizedekanin der Natur- und Lebenswissenschaftlichen Fakultät der Paris Lodron Universität Salzburg intensiv in Fakultätsangelegenheiten eingebunden, wo sie seit 2020 für alle Agenden im Bereich der Biowissenschaften und der 6 biologischen Studien mit >1000 Studierenden zuständig ist.

Als Vizerektorin für Forschung und Nachhaltigkeit ist sie verantwortlich für die Entwicklung der Life Sciences am Standort Salzburg, für allgemeine Forschungsagenden der Universität und Ansprechpartnerin in allen Fragen der Nachhaltigkeit. Zusätzlich umfasst ihr Ressort Arbeitsmedizin und Arbeitssicherheit (gemeinsam mit dem VR für Digitalisierung) sowie das Umweltmanagement.

ACADEMIC CVs and DESCRIPTION of PREVIOUS RESEARCH ACHIEVEMENTS

NAME and CONTACT DETAILS

NAME **Jutta HOREJS-HOECK (≙ Jutta HOREJS-HÖCK)**

CURRENT POSITION Associate Professor at the Dept. of Biosciences, University, Salzburg, Austria, Head of Molecular Immunology Group, Vice Dean of the Faculty of Natural and Life Sciences

PRESENT ADDRESS Department of Biosciences and Medical Biology, University of Salzburg, Hellbrunner Str. 34, A-5020 Salzburg, Austria, Tel: +43-662-8044-5709;

Email: jutta.horejs-hoeck@plus.ac.at, Website: http://www.uni-salzburg.at/horejs-hoeck, http://orcid.org/0000-0002-0984-204X; ResearcherID: E-5010-2011

CITIZENSHIP Austrian

FAMILY STATUS Married, two children (born in 2003 and 2006)

ACADEMIC MILESTONES AND RELEVANT POSITIONS

since 2023	Head of the PLUS Priority Area ACBN (Allergy Cancer BioNano Research Center)
since 2022	Council member of the CIVIS European University Alliance (Health Hub)
2018 -2022	Deputy speaker of the International FWF-funded PhD program: Immunity in Cancer and Allergy (ICA)
since 2015	Vice Dean of the Faculty of Natural Sciences, University of Salzburg, Austria
since 07/2014	Associate Professor at the Dept. of Biosciences, University, Salzburg, Austria
2010-2014	Assistant Professor (tenure track position) at the Dept. of Biosciences, University, Salzburg, Austria

EDUCATION AND SCIENTIFIC CAREER

07/2014	Venia docendi/postdoctoral lecture qualification for the subject areas Immunology and Molecular Biology
2006-2007	Maternity leave, 2nd child (born 7/2006)
2002-2003	Maternity leave, 1st child (born 1/2003)
2000-2010	Postgraduate Researcher at the Novartis Research Institute, Vienna, Austria the Paris-Lodron-University, Salzburg, Austria and the Telethon Institute for Gene-Therapy, Milano, Italy
1/1999	**PhD**, with distinction: Novartis Research Institute, Vienna, University of Salzburg, Austria

MAIN RESEARCH AREAS

Keywords

Tumor immunology, Molecular immunology, *Helicobacter pylori* and the immune system, Cytokine-signaling and feedback inhibition, SOCS proteins, TLRs and NLRs.

Main Research interests and key findings: The group investigates **molecular mechanisms of signaling processes and feedback regulation in immune pathologies**, with a strong focus on signaling pathways in primary human immune cells. Our **main key findings** describe **STAT molecules as crucial players contributing to the expression of type 2 inflammation-related genes**. In addition, we described the **role of SOCS proteins, beyond the regulation of JAK/STAT signaling** (e.g. in signaling pathways induced by pattern recognition receptors) and reported on the **activation of immune cells by endotoxin and other bacterial components**.

FELLOWSHIPS and AWARDS

2015 AAI Careers in Immunology Fellowship Award

2008 Marie Andeßner Mobilitätsförderpreis

2004 Salzburg Land Research Fellowship

2002 Theodor-Körner-Förderungspreis

MOST IMPORTANT RESEARCH ACHIEVEMENTS

Member of reviewing panels, Editorial Boards, Scientific Organizations (selected)

- Austrian Academy of Sciences: Member of the reviewing panel for the Johann Wilhelm Ritter von Mannagetta Prize for Medicine 2018/19, Medical Research Council UK (MRC)
- Member of the American Association of Immunologists (AAI), the Austrian Association of Molecular Life Sciences and Biotechnology (ÖGMBT), the Austrian Society for Allergology and Immunology (ÖGAI) and the Cancer Cluster Salzburg (CCS)

Reviewer activities (selected)

- **JOURNALS**: Cellular and Molecular Immunology, Haematologica, Journal of Hematology and Oncology, Frontiers in Immunology, Molecular Oncology, Cytokine, European Journal of Immunology
- **GRANTS:**Austrian Academy of Sciences, Medical Research Council UK (MRC), Diabetes UK, Israel Science Foundation (ISF), SwissCancer CH

Selected talks

2023 HGSC Conference, Germany

2022 World Immune Regulation Meeting (WIRM), Davos, Switzerland, plenary session

2021 Center for Cancer Research, National Cancer Institute, NIH

2019 University of Zürich

2018 EAACI, Munich

THIRD PARTY FUNDING (2018-2023)

Applicant/PI	Titel/subject	Funding source/origin	Duration		Positions	Volume in €
			from	to		
Horejs-Hoeck	Innate Memory in Helicobacter pylori infection	Austrian Science Fund (FWF), Grant PAT6728223	2023	2027	Postdoc and PhD Student	400.000
Horejs-Hoeck	The NLRP3/eiF2 axis in AML	Austrian Science Fund (FWF), Grant P33969	2021	2025	Postdoc and PhD Student	404.600
Horejs-Hoeck	Effects of NPepZn on the immune system	Ever Neuropharma	2021	2023	Technician	268.200
Horejs-Hoeck	CCS II-IOS: The microenvironment in acute myeloid leukemia	County of Salzburg, Cancer Cluster II	2021	2023	PhD Student	150.375
Horejs-Hoeck (PI and WP Lead)	Directing the immune response through designed nanomaterials (DIRNANO)	EU Horizon 2020 ITN Grant ID: 956544	2020	2024	PhD Student	264.000
Aberger/ Horejs-Hoeck (co-applicant)	Epigenetics of Immunity in Cancer (EPIC)	EU Horizon 2020 Interreg-Project ID: ITAT 1054-EPIC	2019	2022	Technician	150.000
Duschl/ Horejs-Hoeck (co-applicant)	Quantitative detection of bacterial endotoxin by novel nanotechnological approaches (ENDONANO)	EU Horizon 2020, Grant ID: 812661	2019	2022	PhD Student	150.000
Horejs-Hoeck	NLRs in type2 inflammation	FWF Grant W1213	2018	2022	PhD Student	215.000
Horejs-Hoeck	Tumor-microenvironment in AML	County of Salzburg/ Cancer Cluster I	2017	2020	PhD Student	154.000
Duschl/Horejs-Hoeck (co-applicant)	Allergy prevention through oral administration of nitrated proteins	Austria Wirtschaftsservice (AWS)	2017	2020	Technician	61.787

Horejs-Hoeck	NOD1 controls tolerogenic DCs	FWF Grant P29941	2017	2021	Postdoc and PhD Student	389.000
Horejs-Hoeck	Effects of Cerebrolysin	EVER Neuropharma	2016	2021	Technician	205.000
Horejs-Hoeck	Signaling crosstalk between NOD2 and IL-31	FWF Grant P25696	2014	2018	Postdoc and PhD Student	342.000

Lifetime grant income: € 3.68 Mio

PEER-REVIEWED PUBLICATIONS (total ever, 2001– 2023)

PUBLICATIONS (peer reviewed)

Total number of scientific publications: 63

Overall number of citations: >3970

Average citations per item: >63

Hirsch-index: 30

1. Frauenlob, T.; Neuper, T.; Oswald, AL.; Dang, HH.; Unger, M.; Regl, C.; Schaepertoens, V.; Huber, GC.; Wessler, S.; **Horejs-Hoeck, J.** *Helicobacter pylori* induces a novel form of innate immune memory via accumulation of NF-κB proteins**.** *Front Immunol* **2023**, https://doi.org/10.3389/fimmu.2023.1290833, **IF 7.3**
2. Urwanisch, L**#**.; Unger, MS**#**.; Sieberer, H.; Dang, HH.; Neuper, T.; Regl, C.; Vetter, J.; Schaller, S.; Winkler, SM.; Kerschbamer, E.; Weichenberger, CX.; Krenn, PW.; Luciano, M.; Pleyer, L.; Greil, R.; Huber, CG.; Aberger, F.; **Horejs-Hoeck, J**. The Class IIA histone deacetylase (HDAC) inhibitor TMP269 downregulates ribosomal proteins and has anti-proliferative and pro-apoptotic effects on AML cells. *Cancers* **2023**, 15(4) 1039; https://doi.org/10.3390/cancers15041039 **IF 6,6**
3. Johnson, L.; Aglas, L.; Punz, B.; Dang, HH.; Christ, C.; Pointner, L.; Wenger, M.; Hofstaetter, N.; Hofer, S.; Geppert, M.; Andosch, A.; Ferreira, F.; **Horejs-Hoeck, J**.; Duschl, A.; Himly, M. Mechanistic insights into silica nanoparticle-allergen interactions on antigen presenting cell function in the context of allergic reactions *Nanoscale*. **2023** Feb 2;15(5):2262-2275. doi: 10.1039/d2nr05181h. **IF 8,3**
4. Luciano, M.; Krenn, P.W.; **Horejs-Hoeck, J.** The cytokine network in AML. *Front Immunol* **2022**, DOI 10.3389/fimmu.2022.1000996, **IF 8,786**
5. Barbero, F.; Michelini, S.; Moriones, OH.; Patarroyo, J.; Rosell, JF.; Gusta, M.; Vitali, M.; Martín, L.; Canals, F.; Duschl, A.; **Horejs-Hoeck, J**.; Mondragón, L.; Bastús, NG.; Puntes, V. Role of Common Cell Culture Media Supplements on Citrate-Stabilized Gold Nanoparticle Protein Corona Formation, Aggregation State, and the Consequent Impact on Cellular Uptake. Bioconjug Chem. **2022** doi: 10.1021/acs.bioconjchem.2c00232. **IF 6.069**
6. Punz, B.; Johnson, L.; Geppert, M.; Dang, HH.; **Horejs-Hoeck, J**.; Duschl, A.; Himly, M. Surface Functionalization of Silica Nanoparticles: Strategies to Optimize the Immune-Activating Profile of Carrier Platforms. *Pharmaceutics* **2022** doi: 10.3390/pharmaceutics14051103.**IF 6,072**
7. Neuper, T.; Frauenlob, T.; Posselt G.P.; Horejs-Hoeck, J. Beyond the gastric epithelium – the paradox of Helicobacter pylori-induced immune responses. *Current Opinion in Immunology* **2022,** doi: 10.1016/j.coi.2022.102208, **IF 7,5**
8. Frauenlob, T.; Neuper, T.; Mehinagic, M.; Dang, H. H.; Boraschi, D.; **Horejs-Hoeck, J**., Helicobacter pylori Infection of Primary Human Monocytes Boosts Subsequent Immune Responses to LPS. *Front Immunol* **2022**, doi: 10.3389/fimmu.2022.847958, **IF 8,786**
9. Samadi, N.; Koidl, L.; Salzmann, M.; Klems, M.; Komatitsch, N.; Schaffer, D.; Weidmann, E.; Duschl, A.; **Horejs-Hoeck, J.;** Untersmayr, E. Food Allergen Nitration Enhances Safety and Efficacy of Oral Immunotherapy in Food Allergy. *Nutrients* **2022**, doi.org/10.3390/nu14071373, **IF 6,7**
10. Neuper, T.; Weiss, R.; **Horejs-Hoeck, J.** Ripping the Ripoptosome: a novel path for blocking allergic inflammation? *Cellular & Molecular Immunology* ***2022,*** doi: 10.1038/s41423-021-00815-4m, **IF 22,1**
11. Blöchl, C.; Holzner, C.; Luciano, M.; Bauer, R.; **Horejs-Hoeck, J**.; Eckhard, U.; Brandstetter, H.; Huber, C. G., Proteolytic Profiling of Streptococcal Pyrogenic Exotoxin B (SpeB) by Complementary HPLC-MS Approaches. *Int J Mol Sci* **2021, doi***:* 10.3390/ijms23010412, **IF 5,9**
12. Swartzwelter, B.J.; Michelini, S.; Frauenlob, T.; Barbero, F.; Verde, A.; De Luca, A.C.; Puntes, V.; Duschl, A.; **Horejs-Hoeck, J**.; Italiani, P.; Boraschi, D. Innate memory reprogramming by gold nanoparticles depends on the microbial agents that induce memory. *Front Immunol* **2021**, doi: 10.3389/fimmu.2021.751683, **IF 7,5**
13. Michelini, S.; Barbero, F.; Prinelli, A.; Steiner, Ph.; Weiss, R.; Verwanger, T.; Andosh, A.; Lütz-Meindl, U.; Puntes, V.F.; Drobne, D.; Duschl, A.; **Horejs-Hoeck, J**. Gold Nanoparticles (AuNPs) Impair LPS-driven Immune Responses by Promoting a Tolerogenic-like Dendritic Cell Phenotype with Altered Endosomal Structures, *Nanoscale*, **2021**, doi:10.1039/d0nr09153g, **IF 8,3**

14. Urwanisch, L.; Luciano, M.; **Horejs-Hoeck, J.** The NLRP3 Inflammasome and Its Role in the Pathogenicity of Leukemia. *Int. J. Mol. Sci.* **2021**, doi.org/10.3390/ijms22031271, **IF 5,9**
15. Neuper, T., Neureiter. D., Schwarz, H., Sarajlic, M., Bauer, R., Strandt, H., Suchanek, P., Dillon, S.R., Stoecklinger, A., Hammerl, P., Weiss, R., and **Horejs-Hoeck, J**. Reduced allergen-induced lung inflammation in IL-31 transgenic mice, *European Journal of Immunology*, **2021**, doi.org/10.1002/eji.202048547, **IF 6,68**
16. Korotchenko, E.; Schießl, V.; Scheiblhofer, S.; Joubert, I.A.; Strandt, H.; Neuper, T.; Sarajlic,M.; Bauer, R.; Geppert, M.; Joedicke, D.; SWildner, S.; Schaller, S.; Winkler, S.; Gadermaier, G.; **Horejs-Hoeck, J**.; Weiss R.; Laser-facilitated epicutaneous immunotherapy with hypoallergenic beta-glucan neoglycoconjugates suppresses lung inflammation and avoids local side effects in a mouse model of allergic asthma, *Allergy*, **2021**, doi: 10.1111/all.14481, **IF 13,2**
17. Sarajlic M, Neuper T, Vetter J, Schaller S, Klicznik M, Gratz I, Wessler S, Posselt G, **Horejs-Hoeck J.** *H. pylori* modulates DC functions via T4SS/TNFα/p38-dependent *SOCS3* expression. *Cell Commun Signal*, **2020**, doi: 10.1186/s12964-020-00655-1. **IF 5,2**
18. Pinsino, A.; Bastús, N.G.; Busquets-Fité, M.; Canesi, L.; Cesaroni, P.; Drobne,D.; Duschl, A.; Ewart, M.; Gispert, I.; **Horejs-Hoeck, J**.; Italiani,P.; Kemmerling, B.; Kille, P.; Procházková, P.; Puntes, V.F.; Spurgeon, D.J.; Svendsen, C.; Wilde, C.J.; Boraschi, D.; Probing the immune responses to nanoparticles across environmental species. A perspective of the EU Horizon 2020 project PANDORA. *Environ. Sci.: Nano*, **2020**, 7, 3216-3232, doi.org/10.1039/D0EN00732C, **IF 7,9**
19. Chichirau BE, Scheidt T, Diechler S, Neuper T, Huber C, **Horejs-Hoeck J**, Posselt G, Wessler S. Dissecting the *Helicobacter pylori*-regulated transcriptome of B cells. *Pathog Dis*, **2020**, Aug 31:ftaa049. doi: 10.1093/femspd/ftaa049. **IF 3,2**
20. Winter, P.; Stubenvoll, S.; Scheiblhofer, S.; Joubert, I.A.; Strasser, L.; Briganser, C.; Soh, W.T.; Hofer, F.; Kamenik, A.S.; Dietrich, V.; Michelini, S.; Laimer, J.; Lackner, P.; **Horejs-Hoeck, J**.; Tollinger, M.; Liedl,K.R.; Brandstetter, J.; Huber, C.G.; Weiss, R. "In silico design of Phl p 6 variants with altered folding stability significantly impacts antigen processing, immunogenicity and immune polarization", *Frontiers in Immunology*, **2020**, doi: 10.3389/fimmu.2020.01824. **IF 7,5**
21. Klicznik Maria M., Ariane Benedetti, Laura M. Gail, Suraj R. Varkhande, Raimund Holly, Martin Laimer, Angelika Stoecklinger, Andreas Sir, Roland Reitsamer, Theresa Neuper, **Jutta Horejs-Hoeck**, Michael D. Rosenblum, Daniel J. Campbell, Eva M. Murauer, Iris K. Gratz A novel humanized mouse model to study the function of human cutaneous memory T cells in vivo in human skin. *Scientific Reports*, **2020**, doi: 10.1038/s41598-020-67430-7, **IF 4,4**
22. Neuper, T.; Frauenlob, T.; Sarajlic, M.; Posselt, G.; Wessler, S.; **Horejs-Hoeck, J**.; TLR2, TLR4 and TLR10 shape the cytokine and chemokine release of H. pylori-infected human DCs. *Int J Mol Sci,* **2020** May 29;21(11):E3897. doi: 10.3390/ijms21113897, **IF 5,9**
23. Joubert, I.A.; Geppert, M.; Johnson, L.; Mills-Goodlet, T.; Michelini, S.; Korotchenko, E.; Duschl, A.; Weiss, R.; **Horejs-Höck**, **J**.; Himly, M.; Mechanisms of particles in sensitization, effector function and therapy of allergic disease, *Frontiers in Immunology*, **2020**, Jun 30;11:1334. doi: 10.3389/fimmu.2020.01334, **IF 5,1**
24. Korotchenko, E.; Moya, R.; Scheiblhofer, S.; Joubert, I.A.; **Horejs-Hoeck, J.,** Hauser, M.; Calzada, D.; Iraola, V.; Carnés, J.; Weiss, R.; Laser-facilitated epicutaneous immunotherapy with depigmented house dust mite extract alleviates allergic responses in a mouse model of allergic lung inflammation. *Allergy*, **2020** May;75(5):1217-1228. doi: 10.1111/all.14164. Epub 2020 Jan 29. PMID: 31880319, **IF 13,2**
25. Boraschi, D.; Alijagic, A.; Auguste. M.; Barbero, F.; Ferrari, E.; Hernadi, S.; Mayall, C.; Michelini, S.; Navarro Pacheco, N.I., Prinelli, A.; Swart, E.; Swartzwelter, B.J.; Bastús, N.G.; Canesi, L.; Drobne, D.; Duschl, A.; Ewart, M.; **Horejs-Hoeck, J**.; Italiani, P.; Kemmerling, B.; Kille, P.; Prochazkova, Puntes, V.F.; Spurgeon, D.V.; Svendsen, C.; Wilde, C.J.; Pinsino, A.; Addressing Nanomaterial Immunosafety by Evaluating Innate Immunity across Living Species. *Small.* **2020** May 4:e2000598. doi: 10.1002/smll.202000598, **IF 13,3**
26. Himly, M.; Geppert, M.; Hofer, S.; Hofstätter, N.; **Horejs-Höck, J**.; Duschl, A.; When Would Immunologists Consider a Nanomaterial to be Safe? Recommendations for Planning Studies on Nanosafety. *Small* **2020**. DOI smll.201907483 **IF 13,3**
27. Sarajlic, M.; Neuper, T.; Fohrenbach Quiroz, K. T.; Michelini, S.; Vetter, J.; Schaller, S.; **Horejs-Hoeck, J**., IL-1β Induces SOCS2 Expression in Human Dendritic Cells. *Int J Mol Sci* **2019**, 20 (23). DOI 10.3390/ijms20235931, **IF 4,6**
28. Samadi N, Klems M, Heiden D, Bauer R, Kitzmüller C, Weidmann E, Ret D, Ondracek AS, Duschl A, **Horejs-Hoeck J**, Untersmayr E. Nitrated food proteins induce a regulatory immune response associated with allergy prevention after oral exposure in a Balb/c mouse food allergy model, *Allergy*, **2019**, Aug 24. doi: 10.1111/all.14030, **IF 8,7**
29. Aglas L, Gilles S, Bauer R, Huber S, Araujo GR, Mueller G, Scheiblhofer S, Amisi M, Dang HH, Briza P, Bohle B, **Horejs-Hoeck J**, Traidl-Hoffmann C, Ferreira F. Context matters: Th2 polarization resulting from

pollen composition and not from protein-intrinsic allergenicity. *J Allergy Clin Immunol,* **2018**, 18: 30711-30715. doi: 10.1016/j.jaci.2018.05.004, **IF 14,1**

30. Michelini S, Sarajlic M, Duschl A, **Horejs-Hoeck J**. Dendritic cell activation and feedback inhibition in sterile and non-sterile inflammation. *Hum Immunol*, **2018**, 79:610-615. doi: 10.1016/j.humimm.2018.06.002, **IF 2,8**
31. Binder S, Luciano M, **Horejs-Hoeck, J**. The Cytokine Network in Acute Myeloid Leukemia (AML): A Focus on Pro- and Anti-Inflammatory Mediators, *Cytokine and Growth Factor reviews*, **2018**, Oct;43:8-15. doi: 10.1016/j.cytogfr.2018.08.004. **IF 6,4**
32. Strasser L, Schwarz H, Dang HH, Asam C, Ferreira F, **Horejs-Hoeck J**, Huber CG. Unbiased Quantitative Proteomics Reveals a Crucial Role of the Allergen Context for the Activation of Human Dendritic Cells. *Sci Rep*, **2017**, 7:16638. doi: 10.1038/s41598-017-16726-2, **IF 4,1**
33. Li Y, Zhenzhen S, Radauer-Preiml I, Ancuela A, Casals E, Luetz-Meindl U, Cobal M, Zhoumeng L, Jaberi-Douraki M, Italiani P, **Horejs-Hoeck J**, Himly M, Monteiro-Riviere NA, Duschl A, Puntes V, Boraschi D. Bacterial endotoxin (LPS) binds to the surface of gold nanoparticles, interferes with biocorona formation and induces human monocyte inflammatory activation. *Nanotoxicology,* **2017**, 11:1157-1175. doi: 10.1080/17435390, **IF 5,8**
34. Neuper T, Ellwanger K, Schwarz H, Kufer TA, Duschl A, **Horejs-Hoeck J**. NOD1 modulates IL-10 signalling in human dendritic cells. *Sci Rep*, **2017**, 7:1005. doi: 10.1038/s41598-017-00691-x.
35. Schwarz H, Gornicec J, Neuper T, Parigiani MA, Wallner M, Duschl A, Reich J, **Horejs-Hoeck J**. Biological Activity of Masked Endotoxin. *Sci Rep*, **2017**, 7: 44750. doi: 10.1038/srep44750, **IF 4,1**
36. Radauer-Preiml I, Andosch A, Hawranek T, Luetz-Meindl U, Huber C, Wiederstein M, **Horejs-Hoeck J**, Himly M, Boyles MSP, Duschl A. Human allergic response modulated by interactions of allergens with gold nanoparticles – protein corona characterization and basophil response, *Part Fibre Toxicol*, **2016**, 3: 3. doi: 10.1186/s12989-016-0113-0, **IF 8,6**
37. Steiner M, Hawranek T, Schneider M, Harrer A, **Horejs-Hoeck J**, Ferreira F, Himly M. Elevated Toll-like receptor-induced CXCL8 secretion in human blood basophils from allergic donors is independent of Toll-like receptor expression levels. *PlosOne,* **2016** 11: e0149275. doi: 10.1371/journal.pone.0149275, **IF 2,8**
38. Maier E, Mittermaier M, Ess S, Neuper T, Schmiedlechner A, Duschl A, **Horejs-Hoeck J**. Prerequisites for functional Interleukin 31 Signaling and Feedback Regulation by Suppressors of Cytokine Signaling (SOCS). *J Biol Chem*, **2015**, 290: 24747-24759. doi: 10.1074/jbc.M115.661306, **IF 4,7**
39. Machado Y, Freier R, Scheiblhofer S, Thalhamer T, Mayr M, Briza P, Grutsch S, Ahammer L, Fuchs J, Wallnöfer H, Isakovic A, Kohlbauer V, Hinterholzer A, Steiner M, Danzer M, **Horejs-Hoeck J**, Ferreira F, Liedl KR, Tollinger M, Lackner P, Johnson CM, Brandstetter H, Thalhamer J, Weiss R. Fold-stability during endolysosomal acidification is a key factor for allergenicity and immunogenicity of the major birch pollen allergen. *J Allergy Clin Immunol*, **2015**, 7: 1525-1534. doi:10.1016/j.jaci.2015.09.026 , **IF 9,3**
40. Maier, E.; Mittermeir, M.; Ess, S.; Neuper, T.; Schmiedlechner, A.; Duschl, A.; **Horejs-Hoeck, J**. Prerequisites for Functional Interleukin 31 Signaling and Its Feedback Regulation by Suppressor of Cytokine Signaling 3 (SOCS3). *J Biol Chem* **2015**, 290, 24747-24759, doi:10.1074/jbc.M115.661306. IF 4,7
41. Schwarz, H.; Schmittner, M.; Duschl, A.; **Horejs-Hoeck, J**. Residual endotoxin contaminations in recombinant proteins are sufficient to activate human CD1c+ dendritic cells. *PLoS One* **2014**, 9, e113840, doi:10.1371/journal.pone.0113840. **IF 3,2**
42. Maier, E.; Werner, D.; Duschl, A.; Bohle, B.; **Horejs-Hoeck, J**. Human Th2 but not Th9 cells release IL-31 in a STAT6/NF-kappaB-dependent way. *J Immunol* **2014**, 193, 645-654, doi:10.4049/jimmunol.1301836, **IF 5,3**
43. Kofler, S.; Ackaert, C.; Samonig, M.; Asam, C.; Briza, P.; **Horejs-Hoeck, J**.; Cabrele, C.; Ferreira, F.; Duschl, A.; Huber, C.; Brandstetter, H. Stabilization of the dimeric birch pollen allergen Bet v 1 impacts its immunological properties. *J Biol Chem* **2014**, 289, 540-551, doi:10.1074/jbc.M113.518795, **IF 5,2**
44. Ackaert, C.; Kofler, S.; **Horejs-Hoeck, J**.; Zulehner, N.; Asam, C.; von Grafenstein, S.; Fuchs, J.E.; Briza, P.; Liedl, K.R.; Bohle, B.; Ferreira, F.; Brandstetter, H.; Oostingh, G.J.; Duschl, A. The impact of nitration on the structure and immunogenicity of the major birch pollen allergen Bet v 1.0101. *PLoS One* **2014**, 9, e104520, doi:10.1371/journal.pone.0104520, **IF 3,2.**
45. Schwarz, H.; Posselt, G.; Wurm, P.; Ulbing, M.; Duschl, A.; **Horejs-Hoeck, J**. TLR8 and NOD signaling synergistically induce the production of IL-1beta and IL-23 in monocyte-derived DCs and enhance the expression of the feedback inhibitor SOCS2. *Immunobiology* **2013**, 218, 533-542, doi:10.1016/j.imbio.2012.06.007, **IF 3,2**
46. Maier, E.; Duschl, A.; **Horejs-Hoeck, J**. STAT6-dependent and -independent mechanisms in Th2 polarization. *Eur J Immunol* **2012**, 42, 2827-2833, doi:10.1002/eji.201242433, **IF 5,6**
47. **Horejs-Hoeck, J**.; Schwarz, H.; Lamprecht, S.; Maier, E.; Hainzl, S.; Schmittner, M.; Posselt, G.; Stoecklinger, A.; Hawranek, T.; Duschl, A. Dendritic cells activated by IFN-gamma/STAT1 express IL-31

receptor and release proinflammatory mediators upon IL-31 treatment. *J Immunol* **2012**, 188, 5319-5326, doi:10.4049/jimmunol.1101044, **IF 5,8**

48. Posselt, G.; Schwarz, H.; Duschl, A.; **Horejs-Hoeck, J**. Suppressor of cytokine signaling 2 is a feedback inhibitor of TLR-induced activation in human monocyte-derived dendritic cells. *J Immunol* **2011**, 187, 2875-2884, doi:10.4049/jimmunol.1003348, **IF 5,9**
49. Maier, E.; Hebenstreit, D.; Posselt, G.; Hammerl, P.; Duschl, A.; **Horejs-Hoeck, J**. Inhibition of suppressive T cell factor 1 (TCF-1) isoforms in naive CD4+ T cells is mediated by IL-4/STAT6 signaling. *J Biol Chem* **2011**, 286, 919-928, doi:10.1074/jbc.M110.144949, **IF 5,7**
50. Dubrac, S.; Elentner, A.; Ebner, S.; **Horejs-Hoeck, J**.; Schmuth, M. Modulation of T lymphocyte function by the pregnane X receptor. *J Immunol* **2010**, 184, 2949-2957, doi:10.4049/jimmunol.0902151, **IF 5,8**
51. Luft, P.; Oostingh, G.J.; Gruijthuijsen, Y.; **Horejs-Hoeck, J**.; Lehmann, I.; Duschl, A. Patulin influences the expression of Th1/Th2 cytokines by activated peripheral blood mononuclear cells and T cells through depletion of intracellular glutathione. *Environ Toxicol* **2008**, 23, 84-95, doi:10.1002/tox.20309, **IF 3,2**
52. Hebenstreit, D.; Giaisi, M.; Treiber, M.K.; Zhang, X.B.; Mi, H.F.; **Horejs-Hoeck, J**.; Andersen, K.G.; Krammer, P.H.; Duschl, A.; Li-Weber, M. LEF-1 negatively controls interleukin-4 expression through a proximal promoter regulatory element. *J Biol Chem* **2008**, 283, 22490-22497, doi:10.1074/jbc.M804096200, **IF 6,1**
53. Maier, E.; Wirnsberger, G.; **Horejs-Hoeck, J**.; Duschl, A.; Hebenstreit, D. Identification of a distal tandem STAT6 element within the CCL17 locus. *Hum Immunol* **2007**, 68, 986-992, doi:10.1016/j.humimm.2007.10.012, **IF 3,4**.
54. Wirnsberger, G.; Hebenstreit, D.; Posselt, G.; **Horejs-Hoeck, J**.; Duschl, A. IL-4 induces expression of TARC/CCL17 via two STAT6 binding sites. *Eur J Immunol* **2006**, 36, 1882-1891, doi:10.1002/eji.200635972, **IF 5,1**
55. Hebenstreit, D.; Wirnsberger, G.; **Horejs-Hoeck, J**.; Duschl, A. Signaling mechanisms, interaction partners, and target genes of STAT6. Cytokine *Growth Factor Rev* **2006**, 17, 173-188, doi:10.1016/j.cytogfr.2006.01.004, **IF 13,7**
56. Battaglia, M.; Stabilini, A.; Migliavacca, B.; **Horejs-Hoeck,** J.; Kaupper, T.; Roncarolo, M.G. Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. *J Immunol* **2006**, 177, 8338-8347, doi:10.4049/jimmunol.177.12.8338, **IF 6,9**
57. **Horejs-Hoeck, J**.; Hren, A.; Mudde, G.C.; Woisetschlager, M. Inhibition of immunoglobulin E synthesis through Fc gammaRII (CD32) by a mechanism independent of B-cell receptor co-cross-linking. *Immunology* **2005**, 115, 407-415, doi:10.1111/j.1365-2567.2005.02162.x, **IF 4,2**
58. Hebenstreit, D.; Luft, P.; Schmiedlechner, A.; Duschl, A.; **Horejs-Hoeck,** J. SOCS-1 and SOCS-3 inhibit IL-4 and IL-13 induced activation of Eotaxin-3/CCL26 gene expression in HEK293 cells. *Mol Immunol* **2005**, 42, 295-303, doi:10.1016/j.molimm.2004.09.004, **IF 4,3**
59. Hebenstreit, D.; **Horejs-Hoeck, J**.; Duschl, A. JAK/STAT-dependent gene regulation by cytokines. *Drug News Perspect* **2005**, 18, 243-249, doi:10.1358/dnp.2005.18.4.908658, **IF 1,9**
60. Gounni, A.S.; Hamid, Q.; Rahman, S.M.; **Hoeck, J**.; Yang, J.; Shan, L. IL-9-mediated induction of eotaxin1/CCL11 in human airway smooth muscle cells. *J Immunol* **2004**, 173, 2771-2779, doi:10.4049/jimmunol.173.4.2771, **IF 7,2**
61. Stutz, A.M.; **Hoeck, J**.; Natt, F.; Cuenoud, B.; Woisetschlager, M. Inhibition of interleukin-4- and CD40-induced IgE germline gene promoter activity by 2'-aminoethoxy-modified triplex-forming oligonucleotides. J Biol Chem **2001**, 276, 11759-11765, doi:10.1074/jbc.M010260200, **IF 7,4**
62. **Hoeck, J**.; Woisetschlager, M. STAT6 mediates eotaxin-1 expression in IL-4 or TNF-alpha-induced fibroblasts. J Immunol 2001, 166, 4507-4515, doi:10.4049/jimmunol.166.7.4507, **IF 7,3**
63. **Hoeck, J**.; Woisetschlager, M. Activation of eotaxin-3/CCLI26 gene expression in human dermal fibroblasts is mediated by STAT6. *J Immunol* **2001**, 167, 3216-3222, doi:10.4049/jimmunol.167.6.3216 **IF 7,3**

NON-PEER-REVIEWED PUBLICATIONS (2020 – 2021)

64. Luciano, M.; Blöchl, C.; Vetter, J.; Urwanisch, L.; Neuper, T.; Elmer, D.P.; Bauer, R.; Dang, H.H.; Strandt, H.; Neureiter, D.; Krenn, P.; Tesanovic, S.; Rieser, S.; Bergsleitner, O.; Zell, L.; Binder, S.; Schaller. S.; Strunk, D.; Pleyer, L.; Greil, R.; Winkler, S.; Hartmann, T.N.; Huber, C.G.; Aberger, F.; **Horejs-Hoeck, J**.; The NLRP3/eIF2 axis drives cell cycle progression in acute myeloid leukemia *bioRxiv* **2021** DOI.org/10.1101/2021.06.25.449862
65. Elmer, D.P.; Strobl, V.; Stockmaier, G.; Dang, H.H.; Wiederstein, M.; Licha, D.; Strobl, A.; Sternberg, C.; Tesanovic, S.; Grund-Groeschke, S.; Gruber, W.; Wolff, F.; Moriggl, R.; Risch, A.; Reischl, R.; Huber, C.G.; **Horejs-Hoeck, J**.; Aberger, G.; Oncogenic GLI1 and STAT1/3 activation drives immunosuppressive

tryptophan/kynurenine metabolism via synergistic induction of IDO1 in skin cancer cells, *bioRxiv* 2020
DOI.org/10.1101/2020.05.04.074757